MedTrace Logo

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

NCT04342793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-08-11

No results posted yet for this study

Summary

The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients with Non-alcoholic steatohepatitis

Conditions

Interventions

DRUG

Placebo oral tablet

Placebo

DRUG

ALS-L1023 1,200mg

ALS-L1023

DRUG

ALS-L1023 1,800mg

ALS-L1023

Sponsors & Collaborators

  • AngioLab, Inc.

    lead INDUSTRY

Principal Investigators

  • Dae Won Jun, Ph. D. · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2021-05-11
Completion
2021-05-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342793 on ClinicalTrials.gov